Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05RPN
|
|||
| Former ID |
DNC002385
|
|||
| Drug Name |
BMS-488516
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Investigative | [1], [2] | |
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H43N5O3S2
|
|||
| Canonical SMILES |
CC1=CC(=CC(=C1C)C(=O)N2CCN(CC2)C(=O)C)CSC3=CN=C(S3)NC(=O)C4=CC=C(C=C4)CNC(C)C(C)(C)C
|
|||
| InChI |
1S/C33H43N5O3S2/c1-21-16-26(17-28(22(21)2)31(41)38-14-12-37(13-15-38)24(4)39)20-42-29-19-35-32(43-29)36-30(40)27-10-8-25(9-11-27)18-34-23(3)33(5,6)7/h8-11,16-17,19,23,34H,12-15,18,20H2,1-7H3,(H,35,36,40)
|
|||
| InChIKey |
DQPJVNQWPBLBAB-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell-specific kinase (ITK) | Target Info | Inhibitor | [1], [2] |
| KEGG Pathway | Chemokine signaling pathway | |||
| T cell receptor signaling pathway | ||||
| Leukocyte transendothelial migration | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| TCR signaling in naï | ||||
| Class I PI3K signaling events | ||||
| Reactome | Generation of second messenger molecules | |||
| FCERI mediated Ca+2 mobilization | ||||
| WikiPathways | TCR Signaling Pathway | |||
| T-Cell Receptor and Co-stimulatory Signaling | ||||
| TCR signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990 Jun;10(3):200-3. | |||
| REF 2 | ITK inhibitors in inflammation and immune-mediated disorders. Curr Top Med Chem. 2009;9(8):690-703. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.